RD07 / Nanjing Bioheng Biotech - LARVOL DELTA

RD07 in Patients With Advanced Claudin18.2+ Solid Tumors (ChiCTR) - P=N/A | N=18 | Completed | Sponsor: The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University | Not yet recruiting ➔ Completed

Trial completion • Gastric Cancer • Oncology • Solid Tumor • CLDN18

Efficacy and immunomodulatory of Claudin18.2-specific IL-7/XCL1 armored CAR-T cells in digestive tract cancers (SITC 2024) - P=N/A | "All of the patients underwent lymphodepletion consisting of cyclophosphamide, fludarabine or nab-paclitaxel before RD07 infusion at a dose of 0.1–2×107 cells/kg body weight. Consent Written informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.View this table:View inline View popup Download powerpoint Abstract 1458 Table 1 Aggregate baseline characteristics of all patientsDownload figure Open in new tab Download powerpoint Abstract 1458 Figure 1 Waterfall plot and Spider plot for each patient"

CAR T-Cell Therapy • Clinical • Immunomodulating • IO biomarker • Late-breaking abstract • Gastrointestinal Cancer • Hematological Malignancies • Oncology • CLDN18 • IL7